The outcome of patients with cutaneous melanoma has been strongly modified by recent advances obtained with Immune Checkpoint Inhibitors (ICIs). However, despite this breakthrough, durable response to ICIs is limited to a subset of patients. We investigated whether the expression of TRF2, which preserves telomere integrity, and have an effect on tumor immunosurveillance notably by directly recruiting and activating myeloid-derived suppressor cells (MDSCs), could be a prognostic biomarker in patients with relapsed or metastatic melanoma based on different treatment regimens. We evaluated retrospectively the association of TRF2 expressed in melanoma cells in combination with intratumoral CD33+ CD15+ CD14- MDSCs, as detected by immunohistochemistry and quantified by digital analysis, to clinicopathological features and overall survival (OS) among 48 patients treated with ICIs and 77 patients treated with other treatment options. The densities/mm2 of TRF2+ cells (P=.003) and CD33+ cells (P=.004) were individually significantly related to poor OS. In addition, only the combined expression of CD33+/CD15+/CD14- cells/mm2 was significantly correlated to poor OS (P=.017) in the whole study population as well as in patients treated by ICIs (P=.023). There was no significant difference in OS when analyzing the other markers individually or in combination according to the treatment regimen. The pre-treatment assessment of TRF2 expression and CD33+ cells/mm2 along with the density of CD33+/CD15+/CD14- cells/mm2 could assess OS and better predict clinical response of patients with melanoma treated by ICIs.
20 July 2024 in Journal of Investigative Dermatology
Background: Merkel cell carcinoma (MCC) is a rare and aggressive cutaneous neuroendocrine malignancy. Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for patients with metastatic MCC (mMCC). In mMCC, the response duration after cessation of ICIs treatment for complete response (CR) is unknown.Observation: We report a case of a woman in her 70s with metastatic MCC treated in first‐line with avelumab. The treatment was stopped after 2 years of CR. The patient relapsed after 11 months of cessation of treatment and rechallenge with avelumab at the same dosing regimen was decided. The first tumour assessment at 3 months after reintroduction revealed a CR.Discussion: In contrast with observations made for patients who have discontinued ICIs in the metastatic melanoma setting, disease progression is observed after ICIs cessation in mMCC including for patients with low tumour burden and who achieve a CR.Conclusion: The case of our patient underlines this risk of relapse and suggests great caution before stopping ICIs in patients treated for mMCC, even when they are in CR.
Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer, associated with high mortality. Immune checkpoint inhibitors (ICIs) have demonstrated long‐lasting efficiency for treating advanced MCC. Despite a good safety profile, ICI remain associated with non‐negligible risk of immune‐related adverse events (irAEs), which may require treatment discontinuation if they are severe. We report the case of a long‐lasting complete response to Avelumab after rechallenge in a patient with a metastatic MCC who became resistant to this anti‐Programmed cell Death Ligand 1 (anti‐PD‐L1) treatment and who presented severe neuromuscular toxicity during anti‐PD‐1 treatment with Pembrolizumab, without recurrence of the irAE. The potential specificity of therapeutic properties and irAEs of each ICI supports a personalized management of antitumoral immunogenic response and its adverse effects.